Mastercard Incorporated (FRA:M4I)
Germany · Delayed Price · Currency is EUR 493.65
-10.55 (-2.09%)
At close: Aug 1, 2025, 10:00 PM CET
CTI BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | -9 - -5 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | -9 - -5 |
Net Income | - | 12,874 | 11,195 | 9,930 | 8,687 | 6,411 | Upgrade |
Depreciation & Amortization | - | 1,042 | 940 | 887 | 848 | 703 | Upgrade |
Other Amortization | - | 1,830 | 1,622 | 1,586 | 1,371 | 1,072 | Upgrade |
Loss (Gain) From Sale of Investments | - | 29 | 61 | 145 | -645 | -30 | Upgrade |
Stock-Based Compensation | - | 526 | 460 | 295 | 273 | 254 | Upgrade |
Other Operating Activities | - | -481 | -355 | -744 | -155 | -36 | Upgrade |
Change in Accounts Receivable | - | 186 | -546 | -481 | -7 | 1,202 | Upgrade |
Change in Accounts Payable | - | 75 | -99 | 190 | 100 | 26 | Upgrade |
Change in Income Taxes | - | -328 | -300 | -109 | -139 | -39 | Upgrade |
Change in Other Net Operating Assets | - | -973 | -998 | -504 | -870 | -2,339 | Upgrade |
Operating Cash Flow | - | 14,780 | 11,980 | 11,195 | 9,463 | 7,224 | Upgrade |
Operating Cash Flow Growth | - | 23.37% | 7.01% | 18.30% | 30.99% | -11.72% | Upgrade |
Capital Expenditures | - | -474 | -371 | -442 | -407 | -339 | Upgrade |
Cash Acquisitions | - | -2,511 | - | -313 | -4,436 | -989 | Upgrade |
Sale (Purchase) of Intangibles | - | -720 | -717 | -655 | -407 | -369 | Upgrade |
Investment in Securities | - | 306 | -257 | -57 | -55 | -10 | Upgrade |
Other Investing Activities | - | -3 | -6 | -3 | 33 | -172 | Upgrade |
Investing Cash Flow | - | -3,402 | -1,351 | -1,470 | -5,272 | -1,879 | Upgrade |
Long-Term Debt Issued | - | 3,960 | 1,554 | 1,123 | 2,024 | 3,959 | Upgrade |
Long-Term Debt Repaid | - | -1,336 | - | -724 | -650 | - | Upgrade |
Net Debt Issued (Repaid) | - | 2,624 | 1,554 | 399 | 1,374 | 3,959 | Upgrade |
Issuance of Common Stock | - | 224 | 237 | 90 | 61 | 97 | Upgrade |
Repurchase of Common Stock | - | -11,213 | -9,121 | -8,894 | -6,037 | -4,623 | Upgrade |
Common Dividends Paid | - | -2,448 | -2,158 | -1,903 | -1,741 | -1,605 | Upgrade |
Other Financing Activities | - | -23 | - | -20 | -212 | 20 | Upgrade |
Financing Cash Flow | - | -10,836 | -9,488 | -10,328 | -6,555 | -2,152 | Upgrade |
Foreign Exchange Rate Adjustments | - | -199 | 128 | -103 | -153 | 257 | Upgrade |
Net Cash Flow | - | 343 | 1,269 | -706 | -2,517 | 3,450 | Upgrade |
Free Cash Flow | - | 14,306 | 11,609 | 10,753 | 9,056 | 6,885 | Upgrade |
Free Cash Flow Growth | - | 23.23% | 7.96% | 18.74% | 31.53% | -11.29% | Upgrade |
Free Cash Flow Margin | - | 50.79% | 46.26% | 48.36% | 47.96% | 45.00% | Upgrade |
Free Cash Flow Per Share | - | 15.43 | 12.27 | 11.07 | 9.13 | 6.84 | Upgrade |
Cash Interest Paid | - | 571 | 477 | 414 | 399 | 311 | Upgrade |
Cash Income Tax Paid | - | 3,252 | 2,746 | 2,506 | 1,820 | 1,349 | Upgrade |
Levered Free Cash Flow | - | 14,464 | 11,112 | 10,677 | 8,458 | 6,169 | Upgrade |
Unlevered Free Cash Flow | - | 14,868 | 11,471 | 10,971 | 8,728 | 6,406 | Upgrade |
Change in Net Working Capital | - | -2,381 | -445 | -1,371 | -632 | 16 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.